OH-LUBRIZOL
18.1.2024 15:18:27 CET | Business Wire | Press release
Lubrizol Advanced Materials announces that three additional Lubrizol Engineered Polymers sites obtained the International Sustainability and Carbon Certification (ISCC) PLUS certification at the end of last year.
ISCC PLUS is an international sustainability certification for industrial applications, a standard for fully traceable sustainable supply chains that allows companies to track and attribute environmentally friendly raw materials along the entire value chain, through transparent record-keeping and without altering the production process.
The three sites that have achieved this highly valued third-party qualification, the ISCC PLUS certification, are Lubrizol Advanced Materials’ headquarters in Brecksville and the production plants in Avon Lake, Ohio, U.S., and Oevel, Belgium.
As part of Lubrizol’s commitment to sustainability, and our expansion of ESTANE® TPU sustainable solutions, these certifications follow last year’s ISCC PLUS certification of Lubrizol’s facility in Songjiang, China. Our sustainable solutions can be used in different industries, including footwear, electronics, and industrial applications.
“ISCC PLUS enables a fully transparent biomass balance approach and leads to the decrease of the Product Carbon Footprint (PCF) of our final product. This builds up on the launch of our ESTANE RNW TPU solutions which reduces the PCF with the existing equipment used by our customers, without any change in the production process or final material properties,” said Dr. Jesús Santamaria, Global Sustainability Business Director for Lubrizol Engineered Polymers.
“Obtaining ISCC PLUS certification is an important step in ensuring that Lubrizol has a single, consistent, corporate-wide process across our organization to track materials. As we increase our use of bio-based* and renewable materials, Lubrizol’s customers are provided even more confidence in our ability to credibly trace these materials through our manufacturing process,” said Elizabeth Grove, Chief Sustainable Officer, The Lubrizol Corporation.
Expanding the use of alternative feedstocks using the mass balance approach whilst adopting this ISCC PLUS external verification system as an essential tracking element, will support the acceleration of Lubrizol’s global sustainability journey. We are collaborating with our partners and building alliances to develop solutions that bring positive impacts to the environment and society, which outweigh the footprint it takes to produce them.
About Lubrizol
The Lubrizol Corporation, a Berkshire Hathaway company, leverages its unmatched science and innovation to solve complex challenges for customers, drive sustainable and measurable results and help millions of people, communities and businesses around the world move cleaner, create smarter and live better every day. Founded in 1928, Lubrizol operates more than 100 manufacturing facilities, sales and technical offices around the world and has approximately 8,000 employees. For more information, visit www.Lubrizol.com.
ISCC PLUS Certification of three of Lubrizol Engineered Polymers sites help drive the global expansion of ESTANE® TPU sustainable solutions.
*Bio-based content as determined according to ASTM D6866
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240118948548/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom